Novel Radiation Mitigators to Enhance Survival Following Radiation Injury
Categories: “Other Disorders“
Reference #: 2016-029
OTC Contact: Ruchika Nijhara, Ph.D., MBA, CLP (Directory Information | Send a Message)
Acute radiation sickness (ARS) that results from total body irradiation is often fatal and a result of injuries to the bone marrow and gastrointestinal tract. These tissues are uniquely susceptible to radiation-induced toxicity due to the presence of proliferating stem cells. The risk of exposure to lethal doses of radiation is considerable under situations of nuclear disaster and space flight, yet there are no established therapies to address radiation sickness following exposure.
Researchers at Georgetown University and The University of Oklahoma Health Sciences Center have identified protective agents from GI toxicity in models of ARS. These small molecules are useful in mitigating symptoms that occur following lethal dose total body irradiation.
Therapeutic agent for radiation mitigation
- Provides survival benefit to mice exposed to lethal doses of radiation
- May be used to minimize toxicity even after radiation has been delivered
- Reduce the damage in normal tissues caused by radiation
Stage of Development
In vivo proof of concept using murine models.
Milton L Brown, Yali Kong, Courtney Houchen, Sripathi Sureban, Parthasarathy Chandrakesan